Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 279

1.

A double-blind trial of fluoxetine in pathologic skin picking.

Simeon D, Stein DJ, Gross S, Islam N, Schmeidler J, Hollander E.

J Clin Psychiatry. 1997 Aug;58(8):341-7.

PMID:
9515971
2.

Efficacy of fluoxetine in Austrian patients with obsessive-compulsive disorder.

Zitterl W, Meszaros K, Hornik K, Twaroch T, Dossenbach M, Zitterl-Eglseer K, Zapotoczky HG.

Wien Klin Wochenschr. 1999 Jun 4;111(11):439-42.

PMID:
10420495
3.

A multicenter investigation of fixed-dose fluoxetine in the treatment of obsessive-compulsive disorder.

Tollefson GD, Rampey AH Jr, Potvin JH, Jenike MA, Rush AJ, kominguez RA, Koran LM, Shear MK, Goodman W, Genduso LA.

Arch Gen Psychiatry. 1994 Jul;51(7):559-67. Erratum in: Arch Gen Psychiatry 1994 Nov;51(11):864.

PMID:
8031229
4.

Sertraline and fluoxetine treatment of obsessive-compulsive disorder: results of a double-blind, 6-month treatment study.

Bergeron R, Ravindran AV, Chaput Y, Goldner E, Swinson R, van Ameringen MA, Austin C, Hadrava V.

J Clin Psychopharmacol. 2002 Apr;22(2):148-54.

PMID:
11910259
5.

Continuation treatment of OCD: double-blind and open-label experience with fluoxetine.

Tollefson GD, Birkett M, Koran L, Genduso L.

J Clin Psychiatry. 1994 Oct;55 Suppl:69-76; discussion 77-8.

PMID:
7961535
6.
7.

Open-label escitalopram treatment for pathological skin picking.

Keuthen NJ, Jameson M, Loh R, Deckersbach T, Wilhelm S, Dougherty DD.

Int Clin Psychopharmacol. 2007 Sep;22(5):268-74.

PMID:
17690595
8.

Effectiveness of low doses of paroxetine controlled release in the treatment of major depressive disorder.

Trivedi MH, Pigotti TA, Perera P, Dillingham KE, Carfagno ML, Pitts CD.

J Clin Psychiatry. 2004 Oct;65(10):1356-64.

PMID:
15491239
9.
10.
11.

Double-blind, crossover trial of fluoxetine and placebo in children and adolescents with obsessive-compulsive disorder.

Riddle MA, Scahill L, King RA, Hardin MT, Anderson GM, Ort SI, Smith JC, Leckman JF, Cohen DJ.

J Am Acad Child Adolesc Psychiatry. 1992 Nov;31(6):1062-9.

PMID:
1429406
12.

A double-blind, placebo-controlled study of the efficacy and safety of controlled-release fluvoxamine in patients with obsessive-compulsive disorder.

Hollander E, Koran LM, Goodman WK, Greist JH, Ninan PT, Yang H, Li D, Barbato LM.

J Clin Psychiatry. 2003 Jun;64(6):640-7.

PMID:
12823077
13.

Cognitive-behavioral therapy as an adjunct to serotonin reuptake inhibitors in obsessive-compulsive disorder: an open trial.

Simpson HB, Gorfinkle KS, Liebowitz MR.

J Clin Psychiatry. 1999 Sep;60(9):584-90.

PMID:
10520976
14.

An open-label trial of St. John's Wort (Hypericum perforatum) in obsessive-compulsive disorder.

Taylor LH, Kobak KA.

J Clin Psychiatry. 2000 Aug;61(8):575-8.

PMID:
10982200
15.
16.

Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial.

Goldstein DJ, Mallinckrodt C, Lu Y, Demitrack MA.

J Clin Psychiatry. 2002 Mar;63(3):225-31.

PMID:
11926722
17.

Self-injurious skin picking: clinical characteristics and comorbidity.

Wilhelm S, Keuthen NJ, Deckersbach T, Engelhard IM, Forker AE, Baer L, O'Sullivan RL, Jenike MA.

J Clin Psychiatry. 1999 Jul;60(7):454-9.

PMID:
10453800
18.

Fluoxetine treatment for obsessive-compulsive disorder in children and adolescents: a placebo-controlled clinical trial.

Geller DA, Hoog SL, Heiligenstein JH, Ricardi RK, Tamura R, Kluszynski S, Jacobson JG; Fluoxetine Pediatric OCD Study Team..

J Am Acad Child Adolesc Psychiatry. 2001 Jul;40(7):773-9.

PMID:
11437015
19.

High-dose sertraline strategy for nonresponders to acute treatment for obsessive-compulsive disorder: a multicenter double-blind trial.

Ninan PT, Koran LM, Kiev A, Davidson JR, Rasmussen SA, Zajecka JM, Robinson DG, Crits-Christoph P, Mandel FS, Austin C.

J Clin Psychiatry. 2006 Jan;67(1):15-22.

PMID:
16426083
20.

Fluoxetine versus placebo in posttraumatic stress disorder.

Martenyi F, Brown EB, Zhang H, Prakash A, Koke SC.

J Clin Psychiatry. 2002 Mar;63(3):199-206.

PMID:
11926718

Supplemental Content

Support Center